What is the cost of generic dapagliflozin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cost of Generic Dapagliflozin

Generic dapagliflozin 10 mg costs approximately $352 per month (30-day supply) based on the most recent National Average Drug Acquisition Cost (NADAC) data from 2024-2025.

Detailed Pricing Information

Based on the most recent American Diabetes Association Standards of Care guidelines 1:

Current Pricing (2024-2025 Data)

  • NADAC (actual acquisition cost): $352 per month for 10 mg daily dosing
  • AWP (wholesale price): $664-$678 per month for 10 mg daily dosing
  • The NADAC represents what pharmacies actually pay and is more reflective of real-world costs to patients

Historical Pricing Trends

The cost of dapagliflozin has shown variation over recent years:

  • 2023: NADAC $527-$543/month 2, 3
  • 2022: NADAC $511/month 4
  • 2021: NADAC $496/month 5
  • 2020: NADAC $473/month 6
  • 2019: NADAC $446/month 7

The recent decrease to $352/month in 2024-2025 likely reflects increased generic availability and market competition 1.

Important Context

Comparison to Other SGLT2 Inhibitors

Among SGLT2 inhibitors (2024-2025 NADAC pricing) 1:

  • Dapagliflozin 10 mg: $352/month (most affordable)
  • Ertugliflozin 15 mg: $343/month
  • Empagliflozin 25 mg: $586/month
  • Canagliflozin 300 mg: $574/month

Cost Caveats

  • These prices represent average acquisition costs and do not account for:
    • Individual insurance coverage and copays
    • Pharmacy-specific discounts
    • Manufacturer rebates or patient assistance programs
    • Geographic variation
  • Actual out-of-pocket costs to patients may differ substantially from these figures

Clinical Value Consideration

While cost is important, dapagliflozin has demonstrated significant cardiovascular and renal benefits in major trials (DAPA-HF, DAPA-CKD, DECLARE), which should be weighed against medication costs when making treatment decisions 2, 1.

The approximately $352/month cost represents a meaningful reduction from previous years, making this evidence-based therapy more accessible for patients requiring SGLT2 inhibitor therapy.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.